IDH1 and prostate carcinoma: Absence of IDH1 and IDH2 mutations in the melanoma (or low occurrence in GBMs) indicates that these mutations are unlikely to be the major determinants promoting a loss of 5-hmC in melanomas, primary GBMs and prostate cancers.